Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Blood · 1,419 citations
https://doi.org/10.1182/blood-2017-04-779405
A
Amir T. Fathi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
407
Papers
16.2K
Citations
56
h-index
172
i10-index
Amir T. Fathi is an academic researcher from University of Southern California. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 56, co-authored 346 publications.
ORCID: 0000-0003-4907-6447Papers by this author
worksNCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
2021 · Journal of the National Comprehensive Cancer Network · 314 citations
https://doi.org/10.6004/jnccn.2021.0002
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia
2020 · JAMA Oncology · 167 citations
https://doi.org/10.1001/jamaoncol.2020.6343
New directions for emerging therapies in acute myeloid leukemia: the next chapter
2020 · Blood Cancer Journal · 154 citations
https://doi.org/10.1038/s41408-020-00376-1
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
2020 · The Lancet Haematology · 86 citations
https://doi.org/10.1016/s2352-3026(20)30205-2
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
2015 · Blood · 72 citations
https://doi.org/10.1182/blood.v126.23.323.323
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat